ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease
Retrieved on:
Friday, December 2, 2022
Principal investigator, Congress, Safety, Amyloid, ITT, Nature, Research, Cancer, Clinical trial, Neurodegeneration, Dizziness, Parkinson's disease dementia, Patient, MCI, Caregiver, Drug development, Dementia, Quality of life, Mouse, Government budget balance, ADAS-Cog, Nursing, Parkinson's disease, Central nervous system, CNS, Trial of the century, Annual report, Met, SIGMAR1, Cognition, The Michael J. Fox Foundation, Degenerative disease, Epilepsy, ECG, Central nervous system disease, Pain, AD, Death, Hospice, MPH, FRANZCP, Incidence, Communication, Rett syndrome, Therapy, Vital signs, Odds ratio, Clinical Dementia Rating, Medical imaging, Pharmaceutical industry, Fine chemical, Vaccine, Alzheimer's disease, Doctor of Philosophy, MD
ANAVEX2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results.
Key Points:
- ANAVEX2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results.
- ANAVEX2-73 treatment met the primary endpoints and reduced clinical decline on the global cognitive and functional scales over 48 weeks in the analysis of the Intent-to-treat (ITT) population.
- ANAVEX2-73 demonstrated visible improvement in patients with Alzheimers disease.
- On average, patients, who improved cognitively with ANAVEX2-73 treatment, improved by ADAS-Cog cognition score of -4.03 points.